NASDAQ:ICCC - ImmuCell Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $7.20 -0.05 (-0.69 %) (As of 01/17/2019 08:35 AM ET)Previous Close$7.25Today's Range$7.0089 - $7.2452-Week Range$6.38 - $9.30Volume2,347 shsAverage Volume2,355 shsMarket Capitalization$39.77 millionP/E RatioN/ADividend YieldN/ABeta1.24 ProfileDiscussionChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email ImmuCell Corporation, an animal health company, develops, acquires, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company primarily offers First Defense, an orally delivered scours preventive product for newborn calves. It also provides California Mastitis Test, which is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic. In addition, the company is involved in developing purified Nisin treatment for subclinical mastitis in lactating dairy cows; and selling various product applications of its First Defense Technology, including a whey protein concentrate for the nutritional and feed supplement markets. ImmuCell Corporation sells its products to animal health distributors, fleet stores, and direct to farms. The company was founded in 1982 and is headquartered in Portland, Maine. Receive ICCC News and Ratings via Email Sign-up to receive the latest news and ratings for ICCC and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Diagnostic substances Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ICCC Previous Symbol CUSIPN/A Webwww.immucell.com Phone207-878-2770Debt Debt-to-Equity Ratio0.38 Current Ratio3.23 Quick Ratio2.07Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$10.43 million Price / Sales3.79 Cash Flow$0.1327 per share Price / Cash Flow54.24 Book Value$4.31 per share Price / Book1.67Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-160,000.00 Net Margins-13.09% Return on Equity-3.89% Return on Assets-2.69%Miscellaneous Employees47 Outstanding Shares5,490,000Market Cap$39.77 million OptionableNot Optionable ImmuCell (NASDAQ:ICCC) Frequently Asked Questions What is ImmuCell's stock symbol? ImmuCell trades on the NASDAQ under the ticker symbol "ICCC." How were ImmuCell's earnings last quarter? ImmuCell Co. (NASDAQ:ICCC) posted its quarterly earnings results on Tuesday, November, 13th. The biotechnology company reported ($0.05) EPS for the quarter. The biotechnology company earned $2.15 million during the quarter. ImmuCell had a negative net margin of 13.09% and a negative return on equity of 3.89%. View ImmuCell's Earnings History. When is ImmuCell's next earnings date? ImmuCell is scheduled to release their next quarterly earnings announcement on Thursday, February 14th 2019. View Earnings Estimates for ImmuCell. Has ImmuCell been receiving favorable news coverage? Press coverage about ICCC stock has been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ImmuCell earned a media sentiment score of 1.5 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 7.0 out of 10, indicating that recent news coverage is likely to have an effect on the stock's share price in the near future. Who are some of ImmuCell's key competitors? Some companies that are related to ImmuCell include Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Vermillion (VRML), Celldex Therapeutics (CLDX), Riot Blockchain (RIOT), Akers Biosciences (AKER), Achieve Life Sciences (ACHV), GeneNews (GNWSF), Arca Biopharma (ABIO), Fluoropharma Medical (FPMI), BG Medicine (BGMD), Response Genetics (RGDXQ) and Palatin Technologies (PTN). Who are ImmuCell's key executives? ImmuCell's management team includes the folowing people: Mr. Michael F. Brigham, Pres, CEO, Treasurer, Sec. & Director (Age 57)Dr. Joseph H. Crabb, VP & Chief Scientific Officer (Age 63)Ms. Bobbi Jo Brockmann, VP of Sales & Marketing and Director (Age 41)Ms. Elizabeth L. Williams, VP of Manufacturing Operations (Age 62)Mr. A. Gustavo Scaffa, Sr. Director of Quality How do I buy shares of ImmuCell? Shares of ICCC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is ImmuCell's stock price today? One share of ICCC stock can currently be purchased for approximately $7.20. How big of a company is ImmuCell? ImmuCell has a market capitalization of $39.77 million and generates $10.43 million in revenue each year. ImmuCell employs 47 workers across the globe. What is ImmuCell's official website? The official website for ImmuCell is http://www.immucell.com. How can I contact ImmuCell? ImmuCell's mailing address is 56 EVERGREEN DR, PORTLAND ME, 04103. The biotechnology company can be reached via phone at 207-878-2770 or via email at [email protected] MarketBeat Community Rating for ImmuCell (NASDAQ ICCC)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 95 (Vote Outperform)Underperform Votes: 64 (Vote Underperform)Total Votes: 159MarketBeat's community ratings are surveys of what our community members think about ImmuCell and other stocks. Vote "Outperform" if you believe ICCC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICCC will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/17/2019 by MarketBeat.com StaffFeatured Article: How are Outstanding Shares Different from Authorized Shares?